Mark Hammond, CEO of Melbourn Scientific, was one of 100 business leaders recently invited to attend a Downing Street reception to meet with Gordon Brown and Lord Mandelson to congratulate businesses on export success. The event was organised by Lord Davies, recently appointed to the Department for Business, Innovation & Skills.
Prime Minister Gordon Brown thanked all of the companies who attended the reception for everything they were doing for the British economy, British exports and British confidence, adding: “All of you here are successful businesses. All of you have made important innovations in the way you do business. You are helping the country through one of the most difficult financial periods and by increasing your growth rates, making sure that the economy can remain strong for the future.”
Melbourn Scientific, a leading provider of contract analytical, formulation and drug development services for the pharmaceutical, healthcare and biotech sectors, has seen a significant increase in demand from overseas clients as it has added new services to its portfolio. Whilst working with UKTI, Melbourn Scientific has seen sustained growth from across the globe and work with clients from over a dozen different countries now makes up 30% of the company’s turnover.
Business Secretary Lord Mandelson said: “We are passionate, to the point of obsessive, about exports. They are where Britain makes its living in the world economy. The global economic recovery is going to be led more by investment and exports than any early expansion of consumer demand.”
To meet demand from both overseas as well as domestic markets Melbourn Scientific has continued to expand the range of analytical and formulation services it offers, as well as doubling the size of its facilities to support a growing workforce.
Melbourn Scientific was started 20 years ago during a recession so the company is used to responding to challenges in the life science industry.
Mark Hammond comments: “Outsourcing services to an experienced partner is a sound strategy, particularly in a turbulent environment. We work closely with all of our clients, old and new, to share and implement best practices so that we can provide a valuable source of expertise at short notice.
“Our plan over the last year has been to invest in both our staff and the latest equipment so that we can offer new services that are complimentary to the existing services. Working with our clients we have found unique ways to shorten project timelines by running key activities in parallel to ensure timely delivery of project milestones and helping to make projects more cost-effective.”
Melbourn Scientific benefits from being part of the Cambridge cluster and works closely with innovative medical technology, biotech and life-science companies that are world leaders in their field.
Founder and Chairman of Melbourn Scientific, Steve Westcott is overseeing the laboratory expansion which should be complete in the Autumn. He commented:
“Our growth over the past two years has driven a requirement for additional expansion of our laboratory facilities. Our existing state-of-the-art laboratory space already works to the maximum benefit of our clients as it was designed from the ground up for exactly what we do, with key areas already ‘built in’ to allow for future expansion. With the stability storage and formulation laboratory capacity increasing still further we will be able to expand the range of services on offer and greatly increase the amount of projects taking place over a given period. This expansion underpins our commitment to attracting new clients and responds to existing clients’ changing requirements.”
About Melbourn Scientific www.melbournscientific.com
Melbourn Scientific provides high quality analytical and formulation services to the pharmaceutical and healthcare industry. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies.
Melbourn Scientific has invested continually in the latest equipment and provides a range of services: pharmaceutical analysis, physical testing; stability trials; HPLC and inhaled product analysis.
Prime Minister Gordon Brown thanked all of the companies who attended the reception for everything they were doing for the British economy, British exports and British confidence, adding: “All of you here are successful businesses. All of you have made important innovations in the way you do business. You are helping the country through one of the most difficult financial periods and by increasing your growth rates, making sure that the economy can remain strong for the future.”
Melbourn Scientific, a leading provider of contract analytical, formulation and drug development services for the pharmaceutical, healthcare and biotech sectors, has seen a significant increase in demand from overseas clients as it has added new services to its portfolio. Whilst working with UKTI, Melbourn Scientific has seen sustained growth from across the globe and work with clients from over a dozen different countries now makes up 30% of the company’s turnover.
Business Secretary Lord Mandelson said: “We are passionate, to the point of obsessive, about exports. They are where Britain makes its living in the world economy. The global economic recovery is going to be led more by investment and exports than any early expansion of consumer demand.”
To meet demand from both overseas as well as domestic markets Melbourn Scientific has continued to expand the range of analytical and formulation services it offers, as well as doubling the size of its facilities to support a growing workforce.
Melbourn Scientific was started 20 years ago during a recession so the company is used to responding to challenges in the life science industry.
Mark Hammond comments: “Outsourcing services to an experienced partner is a sound strategy, particularly in a turbulent environment. We work closely with all of our clients, old and new, to share and implement best practices so that we can provide a valuable source of expertise at short notice.
“Our plan over the last year has been to invest in both our staff and the latest equipment so that we can offer new services that are complimentary to the existing services. Working with our clients we have found unique ways to shorten project timelines by running key activities in parallel to ensure timely delivery of project milestones and helping to make projects more cost-effective.”
Melbourn Scientific benefits from being part of the Cambridge cluster and works closely with innovative medical technology, biotech and life-science companies that are world leaders in their field.
Founder and Chairman of Melbourn Scientific, Steve Westcott is overseeing the laboratory expansion which should be complete in the Autumn. He commented:
“Our growth over the past two years has driven a requirement for additional expansion of our laboratory facilities. Our existing state-of-the-art laboratory space already works to the maximum benefit of our clients as it was designed from the ground up for exactly what we do, with key areas already ‘built in’ to allow for future expansion. With the stability storage and formulation laboratory capacity increasing still further we will be able to expand the range of services on offer and greatly increase the amount of projects taking place over a given period. This expansion underpins our commitment to attracting new clients and responds to existing clients’ changing requirements.”
About Melbourn Scientific www.melbournscientific.com
Melbourn Scientific provides high quality analytical and formulation services to the pharmaceutical and healthcare industry. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies.
Melbourn Scientific has invested continually in the latest equipment and provides a range of services: pharmaceutical analysis, physical testing; stability trials; HPLC and inhaled product analysis.
